The Overdose Response Strategy (ORS) is an unprecedented and unique public health-public safety partnership between the Office of National Drug Control Policy (ONDCP) and the U.S. Centers for Disease Control and Prevention (CDC) through their support of the High Intensity Drug Trafficking Areas (HIDTA) program and the CDC Foundation. At its core, the ORS is an example of a cross-agency, interdisciplinary collaboration with a single mission of reducing overdose deaths and saving lives across the United States.
WHO WE ARE
The ORS, a partnership between CDC and ONDCP, with support from HIDTA and the CDC Foundation, has grown tremendously since its inception. The program began in 2015 with only five originating HIDTAs, covering 15 states. Today, the program includes all 33 HIDTAs, covering 50 states, the District of Columbia (DC), Puerto Rico and the U.S. Virgin Islands.
The power — and the limitless possibilities — when public health and public safety agencies, each with their own perspectives and experiences, work together to achieve a shared North Star.
“The Overdose Response Strategy is a great experiment in the power of partnerships. The power — and the limitless possibilities — when public health and public safety agencies, each with their own perspectives and experiences, work together to achieve a shared North Star. The ORS began just a few years ago with a blank sheet of paper — and is now a cornerstone of the national strategy to reduce drug overdoses and save lives. The ORS partnership is strong — and continues to get stronger!”
Chauncey Parker, Director, New York/New Jersey HIDTA
WHAT WE DO
The ORS Annual Report describes the current state of the overdose epidemic, outlines the program’s key strategies in 2023, and highlights major accomplishments, activities and success stories of our teams. Click on the icon below to view the report.
In 2022, the Black/African American population in North Dakota made up approximately 3.8% of the state’s population, according to U.S. Census data.1 However, from January to August 2024, preliminary data
The emergence of tianeptine, a prescription drug used for depression but not approved for use in the U.S. and labeled as “potentially dangerous” due to its association with addiction and
Identifying a champion or strategy to advocate for Overdose Detection Mapping Application (ODMAP) utilization among stakeholders can be valuable for strengthening partner relationships and boosting participation. This approach was exemplified
A recent collaboration enabled key information sharing about Tennessee residents arrested in South Carolina on methamphetamine distribution charges to further an existing investigation. The SC DIO passed the felony arrest